Eagle Pharmaceuticals (EGRX) Posts Q2 Loss of 21c/Share

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.21), $0.16 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $3.4 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• BIG3 Basketball to go public via Graf Global merger at $290 million
• Restoration Hardware (RH) PT Raised to $130 at Stifel After Q1 Earnings